MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.75
-0.72
-6.28%
Opening 14:16 02/25 EST
OPEN
11.26
PREV CLOSE
11.47
HIGH
11.49
LOW
10.43
VOLUME
137.36K
TURNOVER
--
52 WEEK HIGH
15.85
52 WEEK LOW
2.470
MARKET CAP
135.63M
P/E (TTM)
-9.0618
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kazia Therapeutics Priced 391,500 Share Offering @AU$ 0.6351/Share
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02346502-2A1283181?access_token=83ff96335c2d45a094df02a206a39ff4
Benzinga · 8h ago
How Is Kazia Therapeutics' (ASX:KZA) CEO Paid Relative To Peers?
This article will reflect on the compensation paid to James Garner who has served as CEO of Kazia Therapeutics Limited...
Simply Wall St. · 01/31 18:06
Kazia, Kintara’s gliblastoma candidates to be evaluated GBM AGILE study
The Global Coalition for Adaptive Research ((GCAR)) in collaboration with Kazia ([[KZIA]] -3.4%) and Kintara ([[KTRA]] -1.3%), have announced the activation of Kazia's paxalisib and Kintara's VAL-083 in Glioblastoma trial
Seekingalpha · 01/06 20:09
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial
Business Wire · 01/06 18:00
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial
GCAR, Kazia, and Kintara Announce Commencement of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE
Business Wire · 01/06 18:00
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial
GCAR, Kazia, and Kintara Announce Commencement of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE
Business Wire · 01/06 18:00
CHU, CHL, FUBO and SKLZ among premarket gainers
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's
Seekingalpha · 01/05 13:27
Kazia Therapeutics Releases Presentation for H.C. Wainwright BIOCONNECT to be Held on January 5, 2021
https://kza.irmau.com/irm/PDF/e1cf8e7a-58f0-4dfc-b810-fa7cbd556d98/KaziapresentstoHCWBIOCONNECT
Benzinga · 01/04 23:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZIA. Analyze the recent business situations of Kazia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 688.37K
% Owned: 5.46%
Shares Outstanding: 12.62M
TypeInstitutionsShares
Increased
4
33.13K
New
6
-428.22K
Decreased
2
35.33K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.75%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Non-Executive Chairman
Iain Ross
Chief Executive Officer/Executive Director
James Garner
Other
Gordon Hirsch
Other
Lilischkis Kimberley
Other
Peng Leong
Other
Stephen Palmer
Other
Justine Stehn
Secretary
Kate Hill
Non-Executive Director
Bryce Carmine
Non-Executive Director
Steven Coffey
  • Dividends
  • Splits
  • Insider Activity
No Data
About KZIA
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.